Leica Biosystems Embeds Aspera into Aperio ePathology Solutions

Aspera faspTM powers high-speed transfers of eSlides within the Aperio ePathology Cloud Solution, ePathAccess, enabling global Pathology collaborations

BIO IT WORLD
Booth 234

CAMBRIDGE, England--()--Aspera, Inc (http://asperasoft.com/)., creators of next-generation technologies that move the world's big data at maximum speed, today announced that the leading provider of ePathology systems, Leica Biosystems, through its Aperio ePathology Solutions, has integrated Aspera's industry leading Connect Server to move large digital images over ePathAccess worldwide.

"The Aspera transfer platform powers the high-speed distribution of data, and integrating with their rich APIs and SDK was straightforward.  Our customers can now move their data at the maximum speed, fully utilizing available bandwidth while drastically reducing the time and effort needed to complete critical projects.'"

Aperio ePathology Solutions begin by converting glass slides to electronic whole slide images (eSlides) that can be managed and distributed inside an institution, within an IT network, or now, across the globe. Uploading these images easily, quickly and securely was the challenge since each eSlide can be very large, and an entire patient case, can be a gigabyte of data. Aspera has helped to overcome this challenge.

Embedded in ePathAccess, using a flexible set of APIs, Aspera fasp (http://asperasoft.com/technology/transport/fasp/) enables secure, high-speed transfer of eSlides and electronic pathology records, within the Aperio Managed Network, ensuring the fastest upload, and eliminating the associated time and travel costs related to expert collaboration. Turnaround time is significantly decreased, making it possible for remote sites with limited access to pathology services to expand patient services.

'Healthcare is benefiting from global collaboration, and with data becoming larger and larger, traditional methods for transferring files are now obsolete," said Anne Brumme, Vice President, Research and Development for Leica Biosystems. "The Aspera transfer platform powers the high-speed distribution of data, and integrating with their rich APIs and SDK was straightforward.  Our customers can now move their data at the maximum speed, fully utilizing available bandwidth while drastically reducing the time and effort needed to complete critical projects.'

'Leica Biosystems' ePathAccess is on the cutting edge, providing solutions to the industry so we are excited to have created this partnership,' said John Wastcoat, vice president, business development at Aspera. 'By enabling their customers to quickly and securely transfer files, collaborations and expert reviews are accelerated resulting in greatly enhanced patient care.'

About Aspera

Aspera is the creator of next-generation transport technologies that move the world's data at maximum speed regardless of file size, transfer distance and network conditions. Based on its patented fasp™ protocol, Aspera software fully utilizes existing infrastructures to deliver the fastest, most predictable file-transfer experience. Aspera's core technology delivers unprecedented control over bandwidth, complete security and uncompromising reliability. More than 2000 organizations across a variety of industries on six continents rely on Aspera software for the business-critical transport of their digital assets.

Please visit www.asperasoft.com and follow us on Twitter @asperasoft for more information.

This information was brought to you by Cision http://news.cision.com

Contacts

Red Lorry Yellow Lorry
USA
Kim Willsher
( 1) 310 569 2603
[email protected]
or
EMEA
Rebecca Edwards
44 (0)20 74038878
[email protected]

 

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.